Nonwhites Twice as Likely to
Receive Injectable Antipsychotics


Research published in the Journal of Clinical Psychiatry shows that of all 901 patients diagnosed with schizophrenia from July 2009 to June 2010 at a community mental health center, white patients were half as likely (OR = .52) than nonwhites to receive long-acting injectable antipsychotics, irrespective of age, gender or comorbid diagnoses including drug abuse. The authors speculate that prescribers may consider nonwhites to be less adherent to antipsychotic medications.

Abstract → 

Related Items:
Psychosis May Be Overdiagnosed in Blacks


Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.


Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.

Previous articleDSM-5 Adds “Behavior” to List of Addictions
Next articleWhose Recovery Is This?! Helping Families Heal
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].